2026-04-14 – Press Releases – www.prnewswire.com
MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivotal IPAX BrIGHT trial[1], marking the first…
